DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES Russian patent published in 2014 - IPC C12N15/00 C12N15/113 A61K31/713 A61K31/7052 A61K48/00 A61P9/10 

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, more specifically to using microRNA (miRNA) for treating pathological cardiac hypertrophy, myocardial infarction or cardiac failure. The method provides introducing a first anti-sense oligonucleotide containing a sequence that is at least partially complementary to the mature nucleotide sequence miR-208a or miR-208b, and a second anti-sense oligonucleotide containing a sequence that is at least partially complementary to the mature nucleotide sequence miR-499 into an individual suffering the cardiac activity.

EFFECT: combined introduction of the above oligonucleotides ensured by manifesting the synergetic effect enables a more effective decrease of the expression or activity of miR-208a or miR-208b and miR-499 in individual's cardiac cells.

30 cl, 7 dwg, 5 ex